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ABSTRACT
Background. Despite an abundance of clinical research on premenstrual and menstrual symptoms,
few epidemiological data provide estimates of the prevalence, incidence, co-morbidity, stability and
correlates of premenstrual dysphoric disorder (PMDD) in the community.
Aims. To describe the prevalence, incidence, 12 co-morbidity factors and correlates of threshold
and subthreshold PMDD in a community sample of young women.
Methods. Findings are based on prospective–longitudinal community survey of 1488 women aged
14–24, who were followed-up over a period of 48 months (follow-up, Nfl 1251) as part of the EDSP
sample. Diagnostic assessments were based on the Composite International Diagnostic Interview
(CIDI) and its 12-month PMDD diagnostic module administered by clinical interviewers.
Diagnoses were calculated using DSM-IV algorithms, but daily ratings of symptoms, as required,
were not available.
Results. The baseline 12-month prevalence of DSM-IV PMDD was 5–8%. Application of the
diagnostic exclusion rules with regard to concurrent major depression and dysthymia decreased the
rate only slightly (5–3%). An additional 18–6% were ‘near-threshold’ cases, mostly because they
failed to meet the mandatory impairment criterion. Over the follow-up period only few new PMDD
cases were observed: cumulative lifetime incidence was 7–4%. PMDD syndrome was stable across
48 months with!10% complete remissions among baseline PMDD cases. The 12-month and
lifetime co-morbidity rates were high (anxiety disorders 47–4%, mood disorders 22–9%; somatoform
28–4%), only 26–5% had no other mental disorder. Particularly high odds ratios were found with
nicotine dependence and PTSD. In terms of correlates increased rates of 4-weeks impairment days,
high use of general health and mental health services, and increased rates of suicide attempts were
found.
Conclusion. In this sample of adolescents and young adults, premenstrual symptoms were
widespread. However, DSM-IV PMDD was considerably less prevalent. PMDD is a relatively
stable and impairing condition, with high rates of health service utilization, increased suicidality and
substantial co-morbidity.
INTRODUCTION
The existence of cyclically recurring pre-
menstrual symptoms of clinical significance has
been recognized for decades (Frank, 1931) and
has been labelled premenstrual syndrome (PMS).
" Address for correspondence: Dr Hans-Ulrich Wittchen, Tech-
nical University of Dresden, Institute of Clinical Psychology and
Psychotherapy, Chemnitzer Str. 46 D-011187 Dresden, Germany.
Subsequent studies in clinical settings and a few
in the community have pointed out that PMS
symptoms are widespread, with significant at-
tendant clinical, public health and socio-econ-
omic implications (Bergsjo et al. 1975; Woods et
al. 1982a, b ; Logue & Moos, 1986). More
stringent attempts to define and operationalize
diagnostic criteria for severe premenstrual con-
ditions, however, have occurred more recently.
The revised 3rd edition of DSM (DSM-III-R,
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APA, 1987) suggested in its appendix for
conditions requiring further study, the category
of late luteal phase dysphoric disorder (LLPDD)
for severe forms of PMS with criteria pre-
dominantly characterized by mood symptoms.
In DSM-IV (APA, 1994) the diagnosis was
retained under the name ‘Premenstrual
Dysphoric Disorder (PMDD) in this appendix,
with more refined and slightly different criteria
along with the suggestion to diagnose and code
this condition as ‘depressive disorders not
otherwise specified’. This latter suggestion re-
ferred to findings of the DSM-IV mood disorder
work group (Hurt et al. 1992) in a clinical
sample of 670 women, keeping prospective
longitudinal ratings, that supported earlier
claims (Halbreich & Endicott, 1985) that many
women will experience a premenstrual depressive
syndrome that cross-sectionally mimics an
atypical form of major depressive disorder.
Despite an abundance of clinical research on
premenstrual and menstrual symptoms, there
are only few reliable and comprehensive
epidemiological data available that do provide
estimates about the prevalence, incidence, risk
factors and correlates of both LLPDD and
PMDD in the community and in clinical settings.
Most of the available epidemiological evidence
is confined to numerous studies that used
questionnaire data to describe the frequency and
the type of PMS symptoms as well as selected
correlates in both adolescent (Cleckner-Smith et
al. 1998) and adult women (Widholm&Kantero,
1971; Van Keep & Lehert, 1981; Andersch et al.
1986; Logue & Moos, 1986, Boyle et al. 1987;
Johnson, 1987; Johnson et al. 1988; Monagle et
al. 1993). Disregarding considerable variation in
instruments, sampling and design of these
studies, there is considerable evidence that the
vast majority of women have at least some PMS
symptom; however, the prevalence of more
severe PMS symptoms seems to be considerably
lower; estimates for variably defined severe
PMS symptomatology vary between 1 and 9%.
As to our current knowledge, there are only two
community studies available, which have used
stricter epidemiological standards concerning
PMS as a syndrome and which provided
prevalence estimates for clinically relevant PMS
conditions. Results from the Zurich cohort
studies (Merikangas et al. 1993; Angst et al.
2001) suggest for their community cohort of 299
women, aged 21 to 35, that according to their
study instrument 8–1% could be regarded as
having severe and 13–6% as having moderate
perimenstrual syndromes. Deuster et al. (1999)
completed the, so far, most powerful survey in
the community. Using telephone interview
survey data incorporating the administration of
theMenstrualDistressQuestionnaire in a sample
of 874 women in Virginia, US, they reported a
cross-sectional prevalence of 8–3% (95% con-
fidence interval 6–4–10–2%) for females aged
18–44. This study is also the only one that
examines associations with a number of social
and behavioural factors including nutrition,
physical exercise, stress and affective state.
Regarding all these studies some general
limitations should be highlighted: (i) none of the
studies provides prevalence estimates of strictly
defined DSM diagnoses of either LLPMD or
PMDD; (ii) almost all studies rely on ques-
tionnaire data (they neither address specifically
and comprehensively DSM symptom criteria,
nor do they take into account the diagnostic
exclusionary criteria or the difficult assessment
criterion of prospective symptom diaries over
subsequent menstrual cycles) ; (iii) to our
knowledge only one study examined specifically
premenstrual symptoms in adolescents ; (iv)
furthermore, very few provide additional epi-
demiological standard measures with regard to
incidence, stability as well as social, clinical and
behavioural risk factors and correlates.
Aims
Given the lack of such data, this paper reports
prevalence and 4-year incidence data for
symptoms and the diagnosis of PMDD ac-
cording to the criteria of DSM-IV in a general
population sample of over 1000 women. It is
noteworthy though, that as in all other available
epidemiological studies, no prospective daily
ratings of PMS symptoms were made as required
by the DSM-IV criteria. As part of the Early
Developmental Stages of Psychopathology study
(EDSP, Wittchen et al. 1998), this prospective
community study provides a wider range of
information concerning vulnerability and risk
factors as well as psychopathological conditions
(co-morbidity with other mental disorders) and
allows incidence and relative stability of this
condition over a period of 4 years to be
estimated.
Premenstrual dysphoric disorder in the community 121
METHOD
The EDSP is based on a 4-year prospective-
longitudinal design with up to three assessment
points (approximately 20 months apart) in a
representative community sample of 3021 ado-
lescents and young adults living in the Munich
area. Age of respondents at baseline (T0) was 14
to 24 years. As the study is designed with special
interest in early stages of disorders and to
increase power, 14- to 15-year-olds were sampled
at twice the probability of persons 16 to 21
years-of-age, and 22- to 24-year-olds were
sampled at half this probability. Furthermore,
this younger cohort (aged 14 to 17 at baseline)
was examined twice over the study periods (first
follow-up investigation (T1)), whereas baseline
18 to 24-year-olds were reinterviewed only once,
as part of the joint final follow-up investigation
(T2), approximately 42 months later after the
baseline assessment.
Sampling of the respondents and baseline
investigation
The EDSP sample was drawn randomly from
the 1994 government population registers of
residents in metropolitan Munich and the
surrounding countries with an expected age
range for the sampled subjects between 14 and
24 (birth cohorts 1970–1981) at the time of the
baseline interview in 1995. A total of 3021
interviews were completed at baseline, resulting
in a response rate of 71%. Detailed descriptions
of the sampling procedures of the baseline
investigation and reasons for non-response have
already been presented elsewhere (Wittchen et
al. 1998; Lieb et al. 2000).
For the purpose of this paper, only female
respondents of this survey were analysed (Nfl
1488) ; response rates for females at baseline
(T0) were 69–7%. The most frequent reasons for
not participating were refusal (18–6%) or lack of
time (3%). The conditional response rate was
86–8% at the first follow-up (T1) and 84–7% at
the (T2) second follow-up. Most frequent
reasons for not participating at the subsequent
follow-up investigations were refusal (6–6% and
9–3%), not locatable, or moved abroad (3–1%
and 1–8%). The age range of the sample at the
final follow-up was 18 to 29. Due to the large
number of respondents, it was technically not
feasible to keep a constant time interval between
the different waves. The first follow-up was
conducted in 1996}1997, an average of 19–7
months after baseline (range: 14 to 25 months).
This wave included only the respondents who
were 14 to 17 years-of-age at baseline (Nfl
1395; birth cohorts 1977–1981). The second
follow-up investigation included all baseline
respondents and was conducted in 1998}1999,
an average of 42 months after the baseline
investigation (range: 34 to 50 months).
Baseline and follow-up sociodemographic
characteristics
Due to the requirement of stable menstruation
patterns, only 1091 (73–3%) of the total of 1488
female participants at baseline completed the
PMS assessment. At T1 among those aged
14–17 at baseline, Nfl 586 out of the total of
591 females (99–2%) completed the PMS as-
sessment, while at T2 among all baseline
participants recontacted, Nfl 1233 out of 1251
(98–6%) completed the PMS assessment.
The sociodemographic characteristics of the
study sample was already described elsewhere in
more detail (Wittchen et al. 1998; Lieb et al.
2000). Briefly, at baseline, 35–5% of the
respondents were in secondary school ; among
these the majority attended Gymnasium (sec-
ondary education between the ages of 10 to 19
that prepares students for entrance to uni-
versity), 25–6% of the respondents attended
university, 9–9% were in job training, 22–9%
were employed and 0–9% were currently un-
employed. The majority of respondents (57–6%)
were still living with their parents and only a few
(4–9%) were married. The vast majority of
respondents were classified as middle class
(60–8%) and 6–6% were grouped as lower social
classes, both of which proportions are consistent
with the demographics of the Munich popu-
lation. Almost all respondents indicated having
had their first menstrual period, the majority
prior to age 14.
At the time of the second follow-up investi-
gation, only a few (12–6%) were still attending a
school other than university (25%), while more
respondents (37–3%) were employed. A lower
proportion of respondents (35–2%) still lived
with their parents, while more subjects lived
with a partner (28–7%). No remarkable changes
were found with regard to the respondents,
reported social class and financial situation. The
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proportion of married respondents doubled
from baseline (4–9%) to second follow-up
(10–3%). The majority (45–8%) indicated the use
of contraceptives in the 12-month period pre-
ceding the T2 assessment.
Assessment of adolescents and young adults
In all three waves of investigation, symptom and
diagnostic assessment were based on the com-
puter assisted version of the Munich-Composite
International Diagnostic Interview (DIA-X}M-
CIDI; Wittchen & Pfister, 1997). The M-CIDI
is an updated version of the World Health
Organization’s CIDI version 1.2 (WHO, 1990)
incorporating questions assessing DSM-IV and
ICD-10 criteria. The M-CIDI allows for the
standardized assessment of symptoms, syn-
dromes and diagnoses of a wide range of DSM-
IV substance use and mental disorders (and
additional various subtypes of main disorders)
along with information about onset, duration,
clinical and psychosocial severity." Detailed
descriptions of M-CIDI along with its assess-
ment procedures and psychometrics have
already been described in detail elsewhere
(Wittchen, 1994; Reed et al. 1998; Wittchen et
al. 1998). In the baseline investigation the lifetime
version of the M-CIDI was used to assess
lifetime and 12-month information. For the two
follow-up investigations, the M-CIDI was modi-
fied to cover the 12-month period prior to the
follow-up interview as well as the remaining
interval between the investigations (12-month-
interval-version). Diagnostic assignment is based
on the M-CIDI diagnostic package ‘DSM-IV
diagnostic algorithms’ (Wittchen & Pfister,
1997). Due to the standardization and com-
puterization of the interview and assignment of
diagnoses, the assessment can be regarded as
highly objective. In each wave, the respondents
were given a special M-CIDI response booklet
with several symptom lists and visual aids to
improve lifetime recall, facilitate memory search,
and help the respondent to answer onset and
recency questions of reported symptoms. Fur-
thermore, the response booklet contained several
scales and questionnaires to assess selected
psychological constructs.
"The complete M-CIDI is available from the authors on request.
M-CIDI-PMDD module and DSM-IV
criteria
In addition to the information concerning the
respondents ’ menstruation history, anthropo-
metric information as well as contraceptive use,
each wave included an identical assessment of
premenstrual syndromes according to criteria of
DSM-IV PMDD. The PMDD module was
administered only in females with at least 3 years
history of regular menstruation and consisted of
a series of questions pertaining to the past 12
months: (a) to assess DSM-IV criterion A,
requires five or more symptoms (i.e. markedly
depressed mood, marked anxiety, tension,
marked affective lability, persistent anger or
irritability) out of a total of 11 symptoms in
most menstrual cycles during the past 12 months,
separate questions evaluated the presence of
DSM-IV symptom criteria during the past 12
months, respectively their presence during the
majority of all menstrual cycles in the past 12
months; (b) supplemented by one question to
ascertain whether these symptoms occurred
consistently in the week before onset of men-
struation and stopped in the week post-menses
(A); (c) three questions were used to evaluate
criterion B for impairment and psychosocial
interference. Criterion C (the disturbance is not
merely an exacerbation of symptoms of another
disorder, such as major depression, or panic
disorder) was assessed whenever the person
fulfilled during the same time period criteria of
both another disorder as well as PMDD.
Criterion D, requiring prospective daily ratings
during at least two consecutive menstrual
cycles was not feasible, therefore in accordance
with DSM-IV PMDD diagnoses in this paper
should be regarded as ‘provisional ’ (prospective
ratings).
Reliability and validity of the M-CIDI
Reliability and procedural validity of the M-
CIDI were tested in several studies. Briefly,
test–retest reliability (retest after an average
period of 39 days, Nfl 60 of the community
sample) was fair to good for substance use
disorders, ranging from kappa (j)fl 0–64 (Yule’s
Yfl 0–80) for drug use disorders to jfl 0–78
(Yule’s Yfl 0–82) for alcohol use disorders
(Wittchen et al. 1998). Procedural clinical val-
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idity was examined in 68 patients comparing M-
CIDI diagnoses with clinicians ’ best-estimate
diagnoses and taking into account all available
information (medical records, diagnostic inter-
view, diagnostic checklist) at the end of the
patients ’ treatment (Reed et al. 1998). Detailed
analyses covering validity and reliability of single
diagnostic criteria and age, frequency, and
quantity information are provided elsewhere
(Wittchen, 1994; Reed et al. 1998; Wittchen et
al. 1998).
Interviewer and interviewer training
In all assessment stages interviews were con-
ducted by a total of 57 clinical interviewers,
mostly graduate psychologists. In addition, 25
professional health research interviewers
recruited from a survey company (Infratest
Gesundheitsforschung) were involved in the base-
line investigation. All interviewers participated
in at least 1 week of training for both the
computerized and the paper-pencil version of
the M-CIDI and several follow-up trainings
throughout each wave as well as at the beginning
of each additional wave. This was followed by at
least ten practice interviews that were closely
monitored and supervised by the staff of the
study. For a more comprehensive overview
about field work methodology see Lieb et al.
2000.
Sample and weighting
As the EDSP is designed with special interest in
early stages of psychopathology, 14- to 15-year-
olds were sampled at twice the probability of 16-
to 21-year-olds, and 22- to 24-year-olds were
sampled at half this probability (see Wittchen et
al. 1998). This sampling strategy allows par-
ticularly precise estimations of measures used
for comparative analyses for the age group of
primary interest, i.e. 14- to 15-year-olds. Due to
the different sampling probabilities, relative
weights inversely proportional to the sampling
fraction are used in the estimation of measures
which are generalized to the sampling frame. In
addition, these weights also account for non-
response according to age, gender and geo-
graphic distribution (urban v. rural) of the
respondents to that of the registered sampling
frame. For data from the first follow-up investi-
gation which include only the 14- to 17-year-
olds, a special weight was computed for the
subpopulation of the younger cohort, also
adjusting for drop-out from baseline to first
follow-up according to age, gender, geographic
distribution and non-response. For data from
the second follow-up, the same weights as those
of the baseline investigation were used, because
there was no selective attrition due to age,
gender, or geographic distribution for which we
needed to adjust.
RESULTS
Prevalence of PMDD at baseline among 14 to
24-year-olds and cumulative incidence
According to the M-CIDI DSM-IV criteria and
algorithms, irrespective of age group examined,
the weighted estimated 12-months prevalence of
PMDD at baseline was 5–8%. There was a
moderate increase (Table 1) of new cases
(unaffected at T0) at the final follow-up of 2–3%
among the previously 14 to 17-year-olds and
2–6% among those aged initially 18–24. The
additional T1 assessment in the younger cohort
suggested a fairly equal incidence increase from
T0 to T1 and T1 to T2, respectively. The
resulting total overall cumulative incidence for
PMDD according to M-CIDI-DSM-IV algo-
rithms across all assessments up to age 29 is
therefore 7–4% (raw N : 104, Nw : 112 cases). We
also examined among baseline and cumulative
incidence cases the effect of the strict application
of diagnostic exclusion criteria of DSM-IV with
regard to major depression and dysthymia, panic
disorder, GAD as well as full somatoform
disorders. Taking current major depression and
dysthymia diagnoses into account, the baseline
rate would drop marginally from 5–8% to 5–3%,
the cumulative incident rate from 7–5% to 6–7%.
Taking the other disorders into account there
was an additional drop of 0–2–0–5%.
Prevalence of premenstrual symptoms in the
total sample, threshold and subthreshold cases
In addition to the PMDD threshold cases,
18–6% of the sample met almost all diagnostic
criteria and were thus classified as subthreshold
PMDD in our study. Prevalence estimates for
full and subthreshold PMDD were identical in
females aged 14–17 years and 18–24 years of age
at baseline. Among subthreshold cases the lack
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Table 1. Prevalence of PMDD at baseline among 14–24-year-olds and 40 months cumulative
incidence
12-months (%weighted) estimates at each assessment and overall cumulative incidence T0}T1}T2
12 mos T0 Incident cases T2 Cum. incidence T0–T2
Nw %w 95%CI Nw %w 95%CI Nw %w 95%CI
Group by age at T0
14–17 13 5–8 3–5–9–3 8 2–3 1–3–4–3 30 6–7 4–9–9–0
18–24 61 5–8 4–2–7–8 22 2–6 1–6–4–2 83 7–7 6–0–10–0
Total 74 5–8 4–4–7–5 30 2–5 1–7–3–7 113 7–4 6–0–9–1
of persistent impairment associated with pre-
menstrual symptoms was by far (72%) the most
frequent reason for not meeting criteria for full
diagnosis.
At baseline only 20–2%, irrespective of age
(design-based F(1,1090)fl 0–0693; Pfl 0–792)
did not endorse any of the 11 symptoms
questions. Among the 79–8% endorsing at least
one PMS symptom as having been present
frequently in the past 12 months, 55–3% reported
having had the symptom(s) in almost all pre-
menstrual episodes : 16–3% reported just one;
15–9% two; 11–9% three; 10–9% four; and
24–8% five or more. The cumulative incidence
rate of PMS symptoms over all three waves was
only slightly higher. In the total sample the
five most frequently endorsed premenstrual
symptoms at baseline and over all three waves
were: physical complaints (T0: 44–9%), affect
lability (41–7%), fatigability (36–6%), depressed
mood (31–4%) and appetite}craving (30–3%).
The rank order of PMDD items among those
with a DSM-IV threshold diagnosis PMDD
was: depressed mood, hopelessness}self-depreci-
ation (90–5%) ranked first, followed by affect
lability (89–7%), irritability}anger (81–5%),
fatigability (78–6%) and physical complaints
(78–1%), anxiety}tension (67%), and decreased
interest (63–3%) (Fig. 1a). The comparison with
subthreshold cases (Fig. 1b) reveals a similar
spectrum of symptoms, however, with markedly
lower frequencies for the following symptoms:
decreased interest (threshold, 74% v. 48–7%;
among subthresholds OR 3–0, 95% CI 1–7–5–2),
depressed mood (93–5% v. 83–9%; OR 2–8,
P! 0–05; 95% CI 1–1–6–9), irritability}anger
(86–9% v 70–6%,flOR 2–8, P! 0–05; 95% CI
1–4–5–7), feeling overwhelmed (49% v. 28–3%;
OR 2–4, P! 0–05; 95% CI 1–5–4–1) and difficulty
in concentrating (54–1 v. 37–7%; OR 2–0,
P! 0–05; 95% CI 1–2–3–2).
Stability of PMDD diagnostic status over the
assessment period
Fig. 2 cross-tabulates baseline diagnostic status
(PMDDfl all DSM-IV criteria are fulfilled,
subthresholdfl just one of diagnostic criteria
is not met, symptomaticflhaving at least
two PMS symptoms, no PMDDflno PMS
symptoms) with the diagnostic status at follow-
up (T1, T2). While only few subjects with no
PMDD at baseline had at least subthreshold
PMDD symptoms at the first or second follow-
up (proportion: 4–6%), 46–7% of those with
baseline subthreshold PMDD symptoms and
48% among those with baseline threshold
PMDD were at least near threshold cases at T1
or T2. The respective proportions for full
remission were 6–7% and 4–9% respectively.
Patterns of 12-month co-morbidity
Table 2 reports the frequency of mental disorders
and their co-morbidity rates among non-PMDD
cases in comparison with threshold and sub-
threshold PMDD cases with their odds ratios
and significance level controlled for by age. At
baseline and in comparison to non-PMDD cases
(57–2% with no disorder), only 26–5% of all
PMDD threshold cases and 39–8% of all
subthreshold cases had no other mental dis-
orders. Thus, threshold (OR3–7, 95%CI 1–9–7–0)
and subthreshold PMDD cases (OR 2–0; 95%
CI 1–4–2–8) were significantly more likely to have
at least one mental disorder and were also more
likely to have at least three 12-month diagnoses
of mental disorders (threshold PMDD, OR 7–3;
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Fig. 1. DSM-IV PMS symptoms. (a) Total prevalence (7) among EDSP females and frequency among those with
PMDD diagnosis (+). (b) Cumulative incidence over 4 years among females, threshold (7, Nfl 104) and subthreshold PMDD
(+, Nfl 321).
95% CI 3–8–13–9; subthreshold, 2–7; 95% CI
1–7–4–4). It is noteworthy – as stated earlier –
that symptoms for example for somatoform
disorders and PMDD were assessed separate-
ly, thus no ‘double counting’ of caseness
occurred.
Most frequent significant associations were
with: (a) anxiety disorders (47–4% PMDD versus
22–5% among non-PMDD cases (odds ratio 3–1
(95% CI 1–7–5–5)), due to associations with
social phobia (OR 4–2 (2–0–8–8) and simple
phobia (OR 3–3 (1–7–6–3), particularly of blood
injury and situational type; (b) all mood dis-
orders (OR 3–0 (1–6–5–7), including bipolar I and
II ; (c) PTSD (11–7 (3–0–46–2) ; (d ) somatoform
disorders (pain, and SSI-4}6, OR 3–4 (1–8–6–6) ;
and (e) nicotine dependence (OR 3–4; 1–8–6–3).
Subthreshold PMDD associations with other
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Fig. 2. Conditional probability of baseline PMDD caseness status at 40 months follow-up (+, threshold PMDD; 7, subthreshold
PMDD; , symptomatic ; *, no PMDD).
Table 2. Twelve months co-morbidity among threshold and subthreshold PMDD cases at
baseline (T0)
No PMDD
(Nfl 828)
PMDD
(Nfl 74)
Subthreshold PMDD
(Nfl 201)
%w %w OR %w OR
Alcohol abuse}dep. 4–9 10–2 2–2 6–7 1–4
Drug abuse}dep. 1–0 2–1 2–2 3–1 3–3*
Nicotine dep. 14–6 36–8 3–4*** 21–1 1–6*
Any affective disorder 12–3 29–8 3–0** 21–0 1–9*
Bipolar I 0–8 5–7 7–9** 3–8 5–3*
Bipolar II 0–6 4–9 8–1** 0–3 0–5
MDD-single 4–3 11–8 3–0* 6–0 1–4
MDD-recurrent 2–6 4–2 1–6 3–5 1–3
Dysthymia 3–9 9–5 2–6* 34–6 1–8*
Any anxiety disorder 22–5 47–4 3–1*** 10–4 3–9*
Panic attacks 2–9 5–8 2–1 5–2 3–7*
Panic disorder 1–4 2–5 1–8 2–7 1–7
Agoraphobia 1–6 5–2 3–4 5–6 1–5
Social phobia 6–0 21–1 4–2*** 10–6 1–8*
Specific phobia 12–5 31–7 3–3*** 19–6 1–7*
Phobia NOS 3–7 6–9 1–9 5–6 1–5
GAD 2–6 1–3 0–5 4–2 1–6
OCD 0–5 1–4 3–1 2–2 4–9*
PTSD 0–8 8–3 11–7*** 1–9 2–5
Any somatoform disorder 10–4 28–4 3–4*** 12–4 1–2
SSI4}6, somatization 1–8 9–7 5–8*** 2–7 1–5
Pain 1–2 4–9 4–3* 2–5 2–0
Any eating disorder 2–1 5–2 2–6 5–5 2–7*
Co-morbidity
None 57–2 26–5 0–3* 39–8 0–5*
Any 42–8 3–5 3–7*** 60–2 2–0***
1 24–3 24–0 1–0 28–6 1–2
2 11–2 12–8 1–2 13–8 1–3
& 3 7–3 36–8 7–3* 17–7 2–7***
Odds ratio (OR) were controlled for by age.
In the co-morbid counts the following groups of DSM-IV diagnoses were considered: any alcohol disorder ; any drug disorder ; nicotine
dependence; any affective disorder ; panic disorder ; agoraphobia; phobia NOS; social phobia; specific phobia; generalized anxiety disorder
(GAD); obsessive–compulsive disorder (OCD); any somatoform disorder ; any eating disorder (anorexia, bulimia, binge eating disorder).
* P! 0–05; ** P! 0–01; *** P! 0–001.
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Table 3. Correlates of threshold and subthreshold PMDD at follow-up (T2)
Non-PMDD
(Nfl 1007)
PMDD
(Nfl 87)
Subthr. PMDD
(Nfl 189)
Indicator %w %w OR (95% CI) %w OR (95% CI)
4 wks impairment 7–5 30–5 5–4*** (2–3–12–3) 13–3 2–3*** (1–5–3–5)
Impairment days}past mo (mean) 0–4 2–0 5–1* (2–4–11–0) 0–4 1–1 (0–6–2–0)
4 wks disability 1–7 4–7 2–9 (0–5–15–6) 1–1 0–6 (0–1–2–9)
Disability days}past mo (mean) 0–1 0–1 1–6 (0–4–7–6) 0
Any mental health treatment 10–2 28–3 3–4** (1–5–8–0) 20–3 2–2** (1–4–3–5)
& 3 GP visits}12 mos 21–9 36–9 2–1* (1–01–4–7) 31–4 1–7** (1–2–2–5)
& 3 visits and specialist}12 mos 4–5 16–9 4–3** (1–4–12–8) 5–3 2–0* (1–0–3–9)
Use of psychotropics 1–5 1–5 1–0 2–1 1–3 (0–4–5–1)
Use of vitamins}minerals 13–7 11–7 0–8 (0–2–3–1) 13–3 0–9 (0–5–1–6)
Suicidal ideation 4–0 8–8 2–3 (0–5–11–0) 6–6 1–7 (0–8–3–5)
Suicide attempts 3–2 15–8 4–4*** (2–0–9–7) 5–0 1–6 (0–7–3–6)
Subjective health rating
Poor 10–7 26–3 3–8*** (1–6–8–9) 22–3 2–0* (1–2–3–6)
Very bad 1–2 8–4 13–0* (1–5–16–6) 6–4 2–4 (0–4–13–4)
 Odds ratios were controlled for age.
Numbers are expressed as percentages unless otherwise stated.
 Impairment and disability days were indicated by their mean and the incidence rate ratio (IRR, calculated with negative binomial regression)
was indicated, instead of the odds ratio.
* P! 0–05; ** P! 0–01; *** P! 0–001.
mental disorders appear to be relatively similar,
however the associations are generally weaker.
The lack of significant associations with PTSD
on the one hand, and the significant associations
with drug}medication abuse or dependence
among subthreshold cases as well as OCD are
noteworthy. The examination of 12-month
associations at follow-up (T2) revealed an almost
identical picture.
We further examined whether baseline PMDD
were more likely than non-PMDD cases to
develop incident anxiety, affective, or somato-
form disorders over the follow-up period. As
compared to non-PMDD cases, PMDD cases
were less likely to develop new anxiety disorders
(incidence rate : 7–6% v. 13–0%). But, they were
significantly more likely to develop new de-
pressive episodes (24–7% v. 9–7%, OR 3–1
(1–4–7–1) disorders, largely due to an increase in
recurrent episodes (single depressive episode
11–2% (T0) v. 6–0%, recurrent, 4–2% (T0) v.
19% (T2) as well as somatoform disorders
(54–7% v. 30–9%, OR 2–7, P! 0–05; 95% CI
1–3–5–7).
Correlates and outcomes
Table 3 reports some selected correlates of
subjects with threshold or subthreshold PMDD
at follow-up. Taking into account that PMDD
cases endorsed that their disturbance has been
associated with significant interference in social
role performance during the majority of cycles
in the past year, it is noteworthy that only
30–5% of PMDD cases as compared to 7–5% of
non-PMDD cases reported acute impairments
in their professional and everyday activities
during the past 4 weeks (OR 5–4; 95% CI
2–3–12–3). The average number of impairment or
disability days per month was 2–6 among full
PMDD and 1–7 among subthreshold cases.
Both PMDD groups were found to be high
utilizers of mental health practitioners, general
health as well as other specialist (gynaecologists)
services in the past 12 months: 28–3% of the
threshold and 20–3% of subthreshold PMDD
cases reported having been in treatment or in
contact with predominantly psychological or
psychotherapeutic services. Also, 36–9% and
31–8%, respectively, had consulted their primary
care doctor more than four times during the
previous 12 months (OR 2–1; 95% CI 1–01–4–7);
contact rates to specialists doctors were par-
ticularly higher in the PMDD group (OR 4–3;
95% CI 1–4–12–8) as compared to the sub-
threshold group. However, no excess rates of
either psychotropic medication use (sedatives,
hypnotics, antidepressives) or the current use of
over the countermedicines for vitamins,minerals
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and tonics were found in comparison to the
control group.
There is a remarkably high risk of suicide
attempts among threshold PMDD cases only
(15–8%; OR 5–7; 95% CI 1–8–18–3), but only
moderately increased risks of suicidal ideation.
There is also a significantly increased risk among
both PMDD groups to report a ‘poor’ or ‘very
bad’ subjective health state.
DISCUSSION
This is, to our knowledge, the first epidemio-
logical study on PMDD using the DSM-IV
criteria in a large community study, based on
standardized diagnostic interviews, instead of
PMS questionnaires, that also included a wider
range of mental disorder. Further strengths of
the study are its prospective-longitudinal design
allowing the determination of incidence rates
and measures of stability as well as of co-
morbidity rates with other mental disorders and
correlates. Among the limitations of the study,
one should keep in mind that in diagnosing
PMDD, we did not take into account all of
the diagnostic exclusions, except for major
depression and dysthymia, that had only a
marginal effect on prevalence estimates. We
were also unable to fulfil DSM-IVs requirement
of using prospective diaries across at least two
menstrual cycles. A further important limitation
of the study is that we examined exclusively
PMDD cases aged 14–24 at baseline and
followed them up over a period of 48 months.
Thus, the results refer to adolescents and young
adults and not to women above this age cut-off,
for which a second high incidence period after
age of 35 has been suggested in the previous
literature.
Premenstrual symptoms are widespread
Using a slightly different symptom list from
previous PMS-related studies, tailored strictly
according to DSM-IVs mandatory symptom
criteria, we first confirmed the findings of
previous studies (Widholm & Kantero, 1971;
Van Keep & Lehert 1981; Andersch et al. 1986;
Logue & Moos, 1986; Boyle et al. 1987; Johnson
1987; Johnson et al. 1988; Monagle et al. 1993;
Cleckner-Smith et al. 1998) that PMS symptoms
in general and particularly among adolescents
are widespread. In each of the assessment waves
more than two-thirds of the female sample
reported at least one PMS symptom being
present during most the menstrual cycles in the
past year, and the high proportion of 35–3% of
women reporting four or more symptoms and
being quite near to DSM-IVs mandatory
threshold count of five or more symptoms is
indeed remarkable. Taking the CIDI’s con-
vention to classify subthreshold disorders by
assigning the diagnosis whenever persons fall
short of just one of the mandatory criteria,
subthreshold PMDD was diagnosed in 18–6%
of the sample. The most frequent reason for not
meeting the full diagnostic criterion was the
impairment criteria (72% of all subthreshold
cases, and neither the symptom count nor the
persistence criterion of DSM-IV). The sub-
stantial size of this subthreshold group under-
lines that consistent premenstrual problems are
quite frequent phenomena of female adolescents
and young adults. It should be mentioned that
such young patients are rarely reported in studies
from specialist services, where actually few
women under age of 25 are obviously seen
(Yonkers, 1997).
We were unable to determine in this study,
whether our finding of relatively high pre-
valences of full DSM-IV PMDD among young
women reflects the weakness of our study of not
having available prospective daily ratings in
making the diagnostic decision, or whether this
finding reflects the fact, that it usually takes
several years before PMDD patients come to
treatment. It might also be possible, referring to
our finding that only slightly more than one-
third of PMDD cases have acute impairments,
that these younger sufferers have a consider-
ably milder symptomatology, than treatment
samples. However, in interpreting these rela-
tively low impairments one has to consider in
epidemiological surveys of conditions of a cyclic
nature, that actually very few cases were in an
acute phase of their illness at the time of the
interview.
PMDD as a full-blown disorder is considerably
less frequent
As already suggested in the majority of previous
publications, PMDD seems to be considerably
less frequent. We estimated a 12-month baseline
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prevalence rate of 5–4% (95% CI 4–4–7–5%)
among 14–24-year-olds. Despite considerable
design and instrumental differences, this estimate
is surprisingly similar to both the Deuster et al.
(1999) finding among 14–44 year-olds : 8–3%
(6–4–10–2%) and the Angst et al. (2001) estimate
of 8–1% severe and 13–6% moderate (similar to
our subthreshold cases) perimenstrual syn-
dromes among 12–35-year-old community sub-
jects. Although using slightly different symptoms
we also confirm, by and large, the Angst et al.
finding of a similar symptom spectrum for
PMDD cases, with depressed mood, hopeless-
ness}self depreciation, irritability}anger, af-
fect lability, fatigability, physical complaints,
anxiety}tension and the feeling of being over-
whelmed as those being the most typical pre-
menstrual problems in this age group. Another
unexpected finding was, that taking into
account concurrent major depression and dys-
tyhmia and other mental disorders as DSM-IV
diagnostic exclusions, the prevalence rate
dropped only slightly by 0–5–1% point. This
finding might highlight a practical problem in
the application of this clinical differential di-
agnostic issue, particularly in epidemiological
research on disorders like PMDD, that refer to
a duration of 12 months (i.e. the past 12
menstrual cycles). In our study we only excluded
PMDD cases from the diagnosis, if there was
evidence for depressive or other mental disorders
over the majority of the past year, however, we
assigned the PMDD diagnosis in cases where we
found for example a single episode of 1 to 3
months duration only. This is in accordance
with the DSM-IV stipulation, that only cases
where the symptoms are merely an exacerbation
should be excluded.
PMDD is a relatively stable and enduring
disorder
In terms of the diagnostic and syndrome stability
over a period of 48 months, our data also
suggest that both threshold and subthreshold
PMS are indeed relatively stable conditions.
Among all baseline threshold cases only 5%
were fully remitted at the final follow-up, 47%
had a least some symptoms, 31% were sub-
threshold and over 17% still had the full
disorder. Similar proportions were found for
subthreshold PMDD cases. On the other hand,
only few of baseline non-PMDD cases developed
into the full disorder (1%). In accordance with
a study by Rosen et al. (1990) and our incidence
findings of only 2–5% incident cases (unaffected
at baseline), this suggests that PMDD among
young adults is a disorder that starts pre-
dominantly early in adolescence and is quite
likely to persist over many years.
PMDD is frequently associated with other
disorders
Our finding of high co-morbidity rates with a
relatively broad spectrum of other mental
disorders was only partially unexpected, given
the lack of similar reports. Given the fact that
PMDD in DSM-IV is grouped under depressive
disorders as well as in light of some depression-
like symptoms in its criteria list, the significant
association with depressive disorders (major
depression and dysthymia) was expected. How-
ever, the relatively high number of bipolar I and
II disorders (about 10%) is remarkable for two
reasons: first, there are some indications from
the retrospective reports on age of onset that,
unlike depressive disorders, which were pre-
dominantly of a secondary nature, the majority
of PMDD cases had significant hypomanic
symptoms prior to baseline. Similarly, the strong
associations with anxiety disorders (47–4%
PMDD v. 24–9% among non-PMDD cases),
due to associations with temporally preceding
social and specific phobia, particularly of blood
injury and situational type, as well as with
posttraumatic stress disorder (PTSD), suggest
that the development of PMDD might be
strongly linked to preceding anxiety disorders as
well as traumatic events and PTSD. It is also
noteworthy that it is very unlikely that the
association to anxiety disorder is simply due to
the fact that anxiety}tension is also a symptom
criterion of PMDD. Clearly this link to anxiety
disorder is in need of further studies, that should
in particular highlight the unexpectedly strong
association with PTSD as well ; we are unaware
of any study or clinical observation at this point
that has highlighted the relevance of trauma,
PTSD and PMDDD development. Given that
our PTSD finding builds partly on retrospective
data, which are subject to recall failure, we are
unable to go beyond this observation. (But the
fact that the majority of triggering traumatic
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events leading to PTSD as well as the pre-
dominant onset of anxiety before age of first
menstruation lends support for this speculation.)
Further indirect evidence comes from our
analyses of incident co-morbid conditions. This
evidence suggests that after the onset of PMDD,
cases reveal a decreased risk for further incident
anxiety disorders as well as no elevated risk for
PTSD and traumatic events. This finding is
unlike to our result for the onset of depressive
and somatoform disorder. For both groups of
disorders we found considerable increases in
incidence after onset of PMDD.
Two other impressive associations already
mentioned in the literature are with nicotine
dependence (Deuster et al. 1999) and somato-
form disorders. Almost 40% of all baseline
PMDD cases and 20% of the subthreshold
cases were regular smokers with a nicotine
dependence syndrome. Although there is some
decrease of the rate of dependent smokers in
both groups at the end of the follow-up period,
this association nevertheless stays impressively
high and significant over the rates of non-
PMDD sufferers. Given the assumed negative
effects of smoking on PMS symptoms it is hard
to speculate about the nature and the potential
causal pathways involved. Clearly more research
is needed to clarify whether regular smoking
among adolescents increases the likelihood of
PMDD; or, whether smoking has to be regarded
as a dysfunctional coping reaction to the PMS
problems; or, whether this association is
mediated by a third vulnerability constellation.
Concerning somatoform disorders our study
confirms significant associations particularly
with two types : persistent pain syndromes (most
frequently : dysmenorrhoea, abdominal and
headache-related) and the shortened somato-
form index SSI 4}6 (Escobar et al. 1989) as a
subthreshold variation of somatization and –
less frequently – of somatization disorder. Since
no sufficiently detailed analyses about age of
onset of premenstrual problems and these soma-
toform conditions are available, we are unable
to decide with sufficient precision whether
premenstrual symptoms trigger the onset of
somatoform disorders or vice versa, likewise our
assessments were not detailed enough to study
the course and the frequency of perimenstrual
pains. Our longitudinal analyses, however
clearly signal that PMDD leads to an increased
risk of secondary pain and somatization. At
baseline only 4–9% of PMDD sufferers had pain
syndromes and 9–7% somatization; at final
follow-up the 12-month rates were 23–5% and
11–6%. Both conditions thus account for the
observed follow-up incidence of somatoform
disorders and conditions.
Correlates of PMDD
Although all PMDD cases in our sample of
adolescents and young adults reported having
had significant interference in several social role
areas during the majority of their menstrual
cycles because of their symptoms, it is note-
worthy that cross-sectionally (past 4 weeks) the
majority of PMDD cases were only mildly
impaired and few acutely disabled. Since our
study provides only 4 weeks impairment and
disability measures for this cyclic monthly
recurring disorder, and since most respondents
were not in an acute phase of their disorder,
these estimates are likely to only provide lower
bound estimates of the actual impairment and
disability during the acute phase.
One unexpected and previously (to our
knowledge) not described finding is the high rate
of PMDD sufferers reporting suicide attempts.
Fifteen per cent reported at least one suicide
attempt during their lifetime. This high rate
could not be explained entirely by the association
with major depressive episode and remained
significant after controlling for the occurrence of
major depression. Yet, at the same time, the risk
for suicidal ideation was not significantly ele-
vated. This finding suggests that among young
PMDD sufferers there might be a group of
particularly suicidal women. Further analyses
will attempt to describe the profile of these
women more comprehensively.
Concerning public health implications, our
findings clearly demonstrate that threshold and
subthreshold PMDD sufferers are high utilizers
of general health, mental health and medical
speciality services. In each of these categories,
PMDD sufferers were much more likely to use
health services than both people not affected by
PMDD and the general population as the whole.
It is remarkable, though, that PMDD cases : (a)
do not use significantly more prescribed psycho-
tropic medications or over the counter (OTC)
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drugs, in particular, vitamins, minerals and
tonics ; and that (b) almost 30% have been in
contact with psychologists and psychotherapists,
but rarely with psychiatric services. Concerning
the use of OTC medications, however, it should
be taken into account that we exclusively asked
for the current (past 4 weeks) use of such
medications. In subsequent analyses we will
particularly focus on PMDD sufferers health
service utilization behaviour to identify the
preferred interventions as well as self-perceived
improvement as a result of the use of such
services.
To summarize, this community survey under-
lines that PMDD is a remarkably complex and
clinically significant condition in adolescent and
young women, leading to prolonged and quite
stable suffering over many years.
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